According to the case study, an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
There are currently 2 FDA-approved chimeric antigen receptor (CAR) T-cell therapies available in the United States,
(Yescarta). Both therapies are indicated to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma; however, Kymriah holds an additional indication to treat B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients.
As part of a report by the American Society of Clinical Oncology, Clinical Cancer Advances 2018, CAR T-cell therapy was
the biggest research breakthrough of 2017. Now, researchers at Moffitt Cancer Center in Tampa, Florida are looking to expand the therapy use to other cancers.
In a new phase 1 trial called
(Therapeutic Immunotherapy with Natural Killer Group 2D [NKG2D]),
researchers are investigating Celyad’s new CAR T therapy CYAD-01 in the treatment of acute myeloid leukemia (AML). While more than half of patients with AML go into remission after treatment with chemotherapy, many relapse due to residual leukemia cells evading both chemotherapy and the immune system. CYAD-01 genetically modifies the patients’ immune cells to express a natural killer receptor that targets leukemia cells.
Click to continue reading on The American Journal of Managed Care.